Vladimir V. Arkhipov

Vladimir V. Arkhipov

Auto-generated profile, based on publicly available information

Vladimir V. Arkhipov

Belgorod State National Research University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2018 in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
Verified
Journal Article
Open access
ASA. P. Solovyova
A. P. Solovyova
DGD. V. Goryachev
D. V. Goryachev
VAV. V. Arkhipov
V. V. Arkhipov

17 December 2020 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
ODO. A. Demidova
O. A. Demidova
VAV. V. Arkhipov
V. V. Arkhipov
MZM. V. Zhuravleva
M. V. Zhuravleva
TAT. A. Alexandrova
T. A. Alexandrova
ААА. А. Александров
А. А. Александров
Herbal medicines make up a large part of all medicinal products in the Russian market. Complex combinations of biologically active substances that are used as components in herbal medicines not only determine their therapeutic efficacy, but can also cause adverse reactions. The aim of this review was to analyse data on adverse effects of herbal medicines, and reasons and mechanisms behind their development. Special attention should be given to hepatotoxic and nephrotoxic effects of biologically active substances that are used as components in herbal medicines, because liver and kidney failure may lead to life-threatening conditions. The paper addresses hepatic adverse effects, including sinusoidal obstruction syndrome, caused by toxic biologically active substances of the pyrrolizidine alkaloids group. The paper summarises data on herbal medicines and toxic biologically active substances causing acute kidney injury and chronic kidney disease. It analyses potential clinically significant interactions that may occur during co-use of herbal and other types of medicines due to their pharmacokinetic and pharmacodynamic interactions. Further research involving collection, systematisation, and analysis of adverse effects of herbal medicines used alone or in combination with other medicinal products is needed to improve the safety of pharmacotherapy.

2 January 2022 in Antibiot Khimioter = Antibiotics and Chemotherapy
Verified
Journal Article
Closed access
PDF file
MZM. V. Zhuravleva
M. V. Zhuravleva
GGG. I. Gorodetskay
G. I. Gorodetskay
TRT. S. Reznikova
T. S. Reznikova
NVN. S. Vasyukova
N. S. Vasyukova
VAV. V. Arkhipov
V. V. Arkhipov
SSS. Yu. Serebrova
S. Yu. Serebrova
The aim of the study is to evaluate the clinical efficacy, safety, and impact of the complex metabolic neuroprotector on the patients’ quality of life (CMN) Cytoflavin in tablets, as well as in the course of stepwise pharmacotherapy of patients with chronic cerebral ischemia (CCI) of various etiologies, followed by meta-analysis, on the basis of a systematic review of published clinical studies.Material and methods. A selection of randomized controlled trials was carried out over the past 15 years, in which CMN Cytoflavin was used in the tablet dosage form or in a stepwise course of therapy in at least 25 patients diagnosed with chronic cerebral ischemia with a total course of therapy of at least 25 days. The assessment of CMP clinical efficacy and the analysis of formalized indicators of clinical efficacy (relative risk, odds ratio, frequency of outcomes, values of absolute and relative benefits, etc.) was carried out.Results and conclusion. 403 publications for 2000–2017 describing the use of CMN Cytoflavin were analyzed. 16 studies were selected for the systematic review, the meta-analysis included 6 randomized clinical trials and one non-randomized study of the use of CMN in patients with CCI. The data of the systematic review and meta-analysis showed a sufficient efficacy of complex metabolic neuroprotector use in patients with chronic cerebral ischemia. However, the meta-analysis revealed significant heterogeneity between the studies. The drug has a beneficial effect on the quality of life of patients, increases the likelihood of a positive outcome in relation to the relief of asthenic and vestibular-atactic syndromes, in relation to complaints of increased fatigue, headache, dizziness, noise in the head, impaired coordination. It improves cognitive functions, exhibits sufficiently high tolerance and safety.

26 October 2023 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
Natalia A. ShnayderNatalia A. Shnayder
Natalia A. Shnayder
Violetta V GrechkinaVioletta V Grechkina
Violetta V Grechkina
VAV. V. Arkhipov
V. V. Arkhipov
RNRegina F. Nasyrova
Regina F. Nasyrova
Scientific relevance. Valproic acid (VPA) is a psychotropic medicinal product, which may be associated with serious adverse drug reactions (ADRs). While pharmacogenetics and pharmacometabolomics can significantly affect the safety of valproates, there are no unified approaches to predicting, preventing, and correcting VPA-induced ADRs.Aim. This study aimed to collate the results of national and international studies on toxic VPA metabolites and to develop a novel personalised approach to assessing the safety and risks of valproate therapy in real-world clinical practice.Discussion. This study analysed national and international publications reflecting the results of preclinical and clinical studies on toxic VPA metabolites submitted to e-Library, PubMed, Scopus, and Google Scholar in 2012–2022. The inclusion criteria were full-text original articles, systematic reviews, meta-analyses, Cochrane reviews, and clinical cases in Russian or English. According to the analysis results, VPA has 20 studied toxic metabolites, which result from hepatic VPA metabolism involving P-oxidation, acetylation (β-oxidation), and glucuronidation enzymes. The functional activity of these enzymes is genetically determined and associated with heterozygous or homozygous carriage of non-functional/low-function single-nucleotide variant alleles in genes encoding these enzymes. The safety of VPA and its compounds can be improved by transferring the results of preclinical and clinical studies into real-world clinical practice using pharmacogenetics-informed pharmacometabolomics. Pharmacogenetics-informed pharmacometabolomics is a novel and personalised approach that helps, based on pharmacogenetic profiling, identify patients at high risk of VPA-induced ADRs, individually select starting and target doses of VPA and its compounds, determine the timing and frequency for therapeutic drug monitoring and monitoring toxic VPA metabolites in biological fluids (blood, saliva, and urine), and select a strategy for the prevention and correction of VPA-induced ADRs, taking into account patients’ individual pharmacometabolic profiles.Conclusions. The quality of medical care for patients with neurological diseases and mental disorders will improve with proper monitoring of VPA-induced ADRs by all entities involved in the medicinal product life cycle; active involvement of neurologists and psychiatrists in the prediction, prevention, and monitoring of the safety of valproate treatment; and inclusion of specific sections on practical pharmacogenetics-informed pharmacometabolomics and pharmacovigilance in the professional training curricula for neurologists and psychiatrists.

1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
MZM.V. Zhuravleva
M.V. Zhuravleva
PKPavel Kamchatnov
Pavel Kamchatnov
NVN.S. Vasyukova
N.S. Vasyukova
VAV.V. Arkhipov
V.V. Arkhipov
EKE.V. Kuznetsova
E.V. Kuznetsova
SSS.Yu. Serebrova
S.Yu. Serebrova
Хроническая ишемия головного мозга (ХИМ) — распространенный синдром, который при отсутствии адекватной терапии характеризуется прогрессирующим течением, нарастанием когнитивных, эмоциональных, двигательных и других нарушений, в итоге приводящих к стойкой инвалидизации пациента. При лечении больных с ХИМ показано применение препаратов с мультимодальным нейропротективным действием. Приведены результаты анализа серии клинических исследований препаратов Мексидол и Мексидол ФОРТЕ у пациентов с ХИМ. Рассматриваются эффекты препарата в отношении когнитивных, эмоциональных, астенических, вегетативных и других проявлений ХИМ. Делается вывод о целесообразности последовательного применения препаратов Мексидол и Мексидол ФОРТЕ у таких больных.

17 April 2024 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
Natalia A. ShnayderNatalia A. Shnayder
Natalia A. Shnayder
Violetta V GrechkinaVioletta V Grechkina
Violetta V Grechkina
VAV. V. Arkhipov
V. V. Arkhipov
RNRegina F. Nasyrova
Regina F. Nasyrova
INTRODUCTION. Pharmacogenetic (PGx) testing plays a significant role in predicting the risk of adverse drug reactions (ADRs) associated with valproic acid (VPA) products, which are among the most prescribed medicinal products in neurology and psychiatry. However, the sensitivity and specificity of PGx screening panels may be insufficient as individual valproate metabolism varies across ethnically/racially diverse patient populations.AIM. The study aimed to identify implementation areas for a personalised approach to the development of PGx panels for assessing the safety and risk of valproate therapy in various ethnic and racial groups residing in the Russian Federation.DISCUSSION. The authors reviewed the results of population studies concerning the frequency of non-functional and low-function alleles of genes encoding isoenzymes that play key roles in VPA P-oxidation in the liver. This review focused on studies published in eLIBRARY.RU, PubMed, Scopus, and Google Scholar in 2012–2022. The inclusion criteria were full-text original articles, systematic reviews, meta-analyses, Cochrane reviews, and clinical cases in Russian or English. The analysis revealed that the need for personalised assessment of the risk and safety of VPA may depend on the frequency of risk alleles for slowing down VPA P-oxidation in the liver across racial and ethnic groups worldwide, and particularly in Russia. The authors identified new areas to implement the personalised approach to the development of PGx panels for assessing the safety and risk of valproate therapy with consideration of the rates of hepatic VPA P-oxidation in patients of different ethnic and racial backgrounds. However, the review of population-based associative genetic research from around the world demonstrated the current lack of clarity in the prospects of translating international findings directly into Russian clinical practice through the development of PGx panels due to Russia’s ethnic/racial diversity and vast territory.CONCLUSIONS. To increase the sensitivity and specificity of Russian PGx panels, bridging studies are required to extrapolate the associations established between the most common risk alleles and VPA P-oxidation disorders in other ethnic groups to a specific population of a specific Russian region.